Skip to main content
Funded Studies

Antony A. Cooper, PhD

Head of the Neurodegeneration & Neurogenomics Program at Garvan Institute of Medical Research

Director at Australian Parkinson's Mission

Location: Sydney Australia

Antony Cooper is a cell and molecular biologist with strong research interests into the causative mechanism(s) of Parkinson’s disease and approaches to ameliorate them. His work has extended into genomics and bioinformatics using transcriptomic data from patient brain regions affected in disease using RNA seq and RNA CapSeq, which was the catalyst for his lab developing bioinformatics and machine-learning models to discover differences within the brain transcriptome of Parkinson’s patients. This transcriptomic analysis extended to identify blood RNA signatures to act as peripheral biomarkers for Parkinson’s diagnosis and/or disease progression that are currently being tested. Recently he has been appointed research director of the Australian Parkinson’s Mission to integrate peripheral biomarkers and genomics into Parkinson’s clinical trials.


Associated Grants

  • Single-molecule Detection of Oligomeric Synuclein in Body Fluids

    2020


  • Verification of a Long, Non-coding RNA in Blood as a Biomarker for Parkinson's Disease

    2014


  • The Role of Noncoding RNAs in Parkinson’s Disease

    2013


  • Validation of ATP13a2 / PARK9 as a Target to Reduce Neurodegeneration Induced by Alpha-Synuclein

    2012


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.